- Home
- LUCY vs QNTM Comparison
LUCY vs QNTM Comparison
Compare LUCY & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- QNTM
- Stock Information
- Founded
- LUCY 2017
- QNTM 1998
- Country
- LUCY United States
- QNTM Canada
- Employees
- LUCY N/A
- QNTM N/A
- Industry
- LUCY Ophthalmic Goods
- QNTM
- Sector
- LUCY Health Care
- QNTM
- Exchange
- LUCY Nasdaq
- QNTM NYSE
- Market Cap
- LUCY 10.3M
- QNTM 8.7M
- IPO Year
- LUCY 2022
- QNTM N/A
- Fundamental
- Price
- LUCY $2.38
- QNTM $7.95
- Analyst Decision
- LUCY Strong Buy
- QNTM
- Analyst Count
- LUCY 1
- QNTM 0
- Target Price
- LUCY $20.00
- QNTM N/A
- AVG Volume (30 Days)
- LUCY 13.9K
- QNTM 1.5M
- Earning Date
- LUCY 05-13-2025
- QNTM 05-13-2025
- Dividend Yield
- LUCY N/A
- QNTM N/A
- EPS Growth
- LUCY N/A
- QNTM N/A
- EPS
- LUCY N/A
- QNTM N/A
- Revenue
- LUCY $1,636,440.00
- QNTM N/A
- Revenue This Year
- LUCY $542.00
- QNTM N/A
- Revenue Next Year
- LUCY N/A
- QNTM N/A
- P/E Ratio
- LUCY N/A
- QNTM N/A
- Revenue Growth
- LUCY 41.99
- QNTM N/A
- 52 Week Low
- LUCY $2.45
- QNTM $2.70
- 52 Week High
- LUCY $27.20
- QNTM $44.72
- Technical
- Relative Strength Index (RSI)
- LUCY 19.08
- QNTM 58.15
- Support Level
- LUCY $2.45
- QNTM $6.45
- Resistance Level
- LUCY $3.48
- QNTM $12.45
- Average True Range (ATR)
- LUCY 0.26
- QNTM 1.65
- MACD
- LUCY -0.05
- QNTM 0.23
- Stochastic Oscillator
- LUCY 0.25
- QNTM 35.06
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.